EyePoint Pharmaceuticals, Inc. (EYPT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jay S. Duker M.D. | President, CEO & Director | 1.19M | -- | 1959 |
| Mr. George O. Elston CPA | Executive VP & CFO | 824.47k | -- | 1965 |
| Dr. Ramiro Ribeiro M.D., Ph.D. | Chief Medical Officer | 742.58k | -- | 1983 |
| Mr. Ron I. Honig Esq. | Chief Legal Officer & Company Secretary | -- | -- | -- |
| Ms. Jennifer Leonard | Chief People Officer & Senior VP of IT | -- | -- | -- |
| Mr. David Scott Jones M.A. | Senior VP & Chief Commercial Officer | 672.08k | -- | 1967 |
| Ms. Isabelle Lefebvre | Chief Regulatory Officer | -- | -- | -- |
| Mr. Michael J. Maciocio | Chief Manufacturing Officer | -- | -- | -- |
| Dr. Marcia Sellos-Moura Ph.D. | Senior VP and Head of Development & Program Management | -- | -- | -- |
| Dr. Anna Kluczewska | CEO of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd | 163.41k | -- | -- |
EyePoint Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 165
Description
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Upcoming Events
August 5, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
EyePoint Pharmaceuticals, Inc. Earnings Date